Citizens reiterates Bicara Therapeutics stock rating on trial progress

🇺🇸 Investing.com (US) —
Citizens reiterates Bicara Therapeutics stock rating on trial progress

AI Summary

Citizens reiterated its stock rating for Bicara Therapeutics, citing progress in clinical trials. The headline does not identify the rating or provide details about the trial results.

Markets Health Bicara Therapeutics Citizens clinical trials trial progress stock rating biotechnology

Read original source →